Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Portland, OR
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Abington, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Abington, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Jenkintown, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Norristown, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Norristown, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Pittsburgh, PA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
North Charleston, SC
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
North Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Nashville, TN
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Richmond, VA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Calgary,
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Meadowbrook Research, Inc.
mi
from
Scottsdale, AZ
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Meadowbrook Research, Inc.
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Psychiatric Centers at San Diego
mi
from
San Marcos, CA
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Psychiatric Centers at San Diego
mi
from
San Marcos, CA
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Alpine Clinical Research Center
mi
from
Boulder, CO
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Alpine Clinical Research Center
mi
from
Boulder, CO
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Miami Research Associates
mi
from
Miami, FL
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Miami Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Capstone Clinical Research
mi
from
Libertyville, IL
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Pedia Research LLC
mi
from
Owensboro, KY
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Pedia Research LLC
mi
from
Owensboro, KY
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
ProMed Pediatrics
mi
from
Kalamazoo, MI
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
ProMed Pediatrics
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Children's Specialized Hospital
mi
from
Toms River, NJ
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Children's Specialized Hospital
mi
from
Toms River, NJ
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
North Carolina Neuropsychiatry PA
mi
from
Chapel Hill, NC
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
North Carolina Neuropsychiatry PA
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Ohio State University
mi
from
Columbus, OH
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
IPS Research Company
mi
from
Oklahoma City, OK
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
CNS Research Institute
mi
from
Philadelphia, PA
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
CNS Research Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Claghorn-Lesem Research Clinic
mi
from
Bellaire, TX
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Claghorn-Lesem Research Clinic
mi
from
Bellaire, TX
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
ADHD Clinic of San Antonio
mi
from
San Antonio, TX
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
ADHD Clinic of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
NeuroScience, Inc.
mi
from
Herndon, VA
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
NeuroScience, Inc.
mi
from
Herndon, VA
Click here to add this to my saved trials
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated:  7/8/2015
Monarch Medical Research
mi
from
Norfolk, VA
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.
Status: Enrolling
Updated: 7/8/2015
Monarch Medical Research
mi
from
Norfolk, VA
Click here to add this to my saved trials
Pioglitazone and Quetiapine XR Pharmacogenetic Study
Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders
Status: Enrolling
Updated:  7/8/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Pioglitazone and Quetiapine XR Pharmacogenetic Study
Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders
Status: Enrolling
Updated: 7/8/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
Status: Enrolling
Updated:  7/9/2015
Oregon Health and Science University
mi
from
Portland, OR
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
Status: Enrolling
Updated: 7/9/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Mindfulness Meditation Format Pilot Study
Mindfulness Meditation Format Pilot Study
Status: Enrolling
Updated:  7/9/2015
Oregon Health and Science University
mi
from
Portland, OR
Mindfulness Meditation Format Pilot Study
Mindfulness Meditation Format Pilot Study
Status: Enrolling
Updated: 7/9/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Sleep and Delirium in the Intensive Care Unit (ICU)
Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.
Status: Enrolling
Updated:  7/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study of Sleep and Delirium in the Intensive Care Unit (ICU)
Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.
Status: Enrolling
Updated: 7/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Naltrexone for Impulse Control Disorders in Parkinson's Disease
Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease
Status: Enrolling
Updated:  7/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Naltrexone for Impulse Control Disorders in Parkinson's Disease
Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease
Status: Enrolling
Updated: 7/13/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Boulder Community Hospital
mi
from
Boulder, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Porter Adventist Hospital
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
St. Joseph Hospital
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Rose Medical Center
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
Swedish Medical Center
mi
from
Englewood, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated:  7/13/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Creatine in Treating Patients With Cancer-Associated Weight Loss
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss
Status: Enrolling
Updated: 7/13/2015
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials